atrial natriuretic peptide Report issue

Biologics Peptide Experimental
AACT ChEMBL Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Atrial Natriuretic Peptide (ANP) or atrial natriuretic factor (ANF) is a natriuretic peptide hormone secreted from the cardiac atria that in humans is encoded by the NPPA gene. Natriuretic peptides are a family of hormone/paracrine factors that are structurally related. The main function of ANP is causing a reduction in expanded extracellular fluid (ECF) volume by increasing renal sodium excretion. ANP is synthesized and secreted by cardiac muscle cells in the walls of the atria in the heart. These cells contain volume receptors which respond to increased stretching of the atrial wall due to increased atrial blood volume.   Wikipedia

Chemistry

  • SMILES: CC[C@H](C)[C@@H]1NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)CNC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)CNC1=O
  • InChIKey: NSQLIUXCMFBZME-MPVJKSABSA-N
  • Mol. Mass: 3080.5
  • ALogP: Missing data
  • ChEMBL Molecule:
    carperitide  
More Chemistry

Pharmacology

Alternative names

alpha-atrial natriuretic peptide, human | alpha-hanp | alpha-human atrial natriuretic peptide | atrial natriuretic peptide | atrial natriuretic peptide precusor a, human | atrial natriuretic polypeptide | atriopeptin | carperitide | carperitide (recombinant) | human atrial natriuretic peptide | natriuretic peptide precursor a, human | nppa protein, human | sun-4936

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Hypernatremia

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Acute Kidney Injury (Phase 3)

Cardiomyopathies (Phase 2)

Heart Failure (Phase 4)

Heart Failure, Diastolic (Phase 2)

Hypertension ()

Hypertrophy, Left Ventricular (Phase 2)

Optic Nerve Glioma (Phase 3)

Renal Insufficiency (Phase 4)

Respiratory Distress Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue